Antigen recognition strength regulates the choice between extrafollicular plasma cell and germinal center B cell differentiation

Didrik Paus,1,2 Tri Giang Phan,1,2 Tyani D. Chan,1,2 Sandra Gardam,1,2 Antony Basten,1,2 and Robert Brink1,2

1Centenary Institute of Cancer Medicine and Cell Biology, Newtown NSW 2042, Australia
2 Faculty of Medicine, University of Sydney, Camperdown NSW 2006, Australia

B cells responding to T-dependent antigen either differentiate rapidly into extrafollicular plasma cells or enter germinal centers and undergo somatic hypermutation and affinity maturation. However, the physiological cues that direct B cell differentiation down one pathway versus the other are unknown. Here we show that the strength of the initial interaction between B cell receptor (BCR) and antigen is a primary determinant of this decision. B cells expressing a defined BCR specificity for hen egg lysozyme (HEL) were challenged with sheep red blood cell conjugates of a series of recombinant mutant HEL proteins engineered to bind this BCR over a 10,000-fold affinity range. Decreasing either initial BCR affinity or antigen density was found to selectively remove the extrafollicular plasma cell response but leave the germinal center response intact. Moreover, analysis of competing B cells revealed that high affinity specificities are more prevalent in the extrafollicular plasma cell versus the germinal center B cell response. Thus, the effectiveness of early T-dependent antibody responses is optimized by preferentially steering B cells reactive against either high affinity or abundant epitopes toward extrafollicular plasma cell differentiation. Conversely, responding clones with weaker antigen reactivity are primarily directed to germinal centers where they undergo affinity maturation.
stochastically follow either response pathway such that the original specificities recruited into the response are represented equally in both the extrafollicular and early GC populations (11, 12). Alternatively, differential recognition of antigen by B cell receptors (BCRs) expressed on individual B cells may influence their subsequent responses, in which case the specificities represented in the extrafollicular and early GC populations would differ. Evidence for the stochastic model has come from analysis of responses to the haptens (4-hydroxy-3-nitrophenyl)acetyl (NP), where both low and high affinity clones have been detected at similar frequencies in extrafollicular foci and early GCs (11). However, the stochastic model is difficult to reconcile with data from other systems, indicating that relatively high affinity specificities can dominate the initial T-dependent antibody response (13–15). The question of whether the nature of the interaction between antigen and BCR influences cell fate during early T-dependent responses is therefore still controversial.

The two major variables that impact on the interaction of an antigen with a BCR are the affinity of the epitope for the receptor’s monovalent Fab and the density or valency of the epitope on the antigen. Manipulation of either of these variables can produce profound changes in the responses of B cells to BCR stimulation in vitro (16–19) as well as to T-independent responses (20, 21) and induction of self-tolerance (22–24) in vivo. The uncertainty surrounding the impact of antigen affinity and density on early T-dependent B cell responses is due largely to the difficulty of tracking responding B cells in vivo and defining the precise nature of their initial interaction with the antigen. To overcome these problems, we have developed gene-targeted mice expressing H and L chains of HyHEL10 anti–hen egg lysozyme (HEL) mAb (SWHEL), in which B cells express a defined anti-HEL BCR and are capable of normal Ig class switching and SHM (6, 25). By challenging CD45-allotyped marked SWHEL B cells with HEL coupled to sheep red blood cells (SRBC) in an adoptive transfer system, T-dependent responses can be accurately tracked in vivo by both immunohistology and flow cytometry (6). In this study, SWHEL B cells were challenged with a range of recombinant HEL proteins engineered to recognize the SWHEL BCR over a 10,000-fold affinity range and coupled to SRBC at different antigen densities. Examination of the early T-dependent responses generated by the SWHEL B cells indicated that decreasing either antigen affinity or density profoundly reduced the extrafollicular plasma cell response but had minimal impact on the GC reaction. Thus, although the requirements for GC entry are not stringent, responding B cells require a strong initial interaction with the antigen to contribute significantly to the early plasma cell response. These results reveal that the initial antigen–BCR interaction plays a fundamental role in organizing early T-dependent B cell responses.

RESULTS

Generation of HEL mutants with varying affinities for the SWHEL BCR
The role played by initial antigen affinity in regulating early B cell responses was investigated by generating a panel of recombinant HEL molecules with the capacity to bind over a wide affinity range to the anti-HEL BCR expressed on SWHEL B cells. SWHEL mice carry a targeted Ig heavy chain variable region gene with a light chain transgene that together encode BCRs with the specificity of the HyHEL10 mAb (25). Because the affinity of WT HEL for HyHEL10 is very high ($2 \times 10^{10} \text{M}^{-1}$) (26), it was necessary to create HEL mutants that bound HyHEL10 with lower affinities more typical of those found in primary B cell responses. Arginine 21, arginine 73, and aspartate 101 of HEL all form direct contacts with the Ig heavy chain of HyHEL10 (reference 26; Fig. 1 A) and were mutated to glutamine (R21HELQ), glutamate (R73HELE), and arginine (D101HELR) both singly and in combination. Recombinant HEL mutants were expressed in yeast and purified from culture supernatants. All retained lysozyme enzymatic activity and differed less than twofold from WT HEL (HELWT) in their affinity for the noncompetitive anti-HEL mAb HyHEL9 (unpublished data), indicating that these point mutations did not affect overall protein folding.

As expected, the affinities of the various HEL mutants for HyHEL10 varied widely. Competitive ELISA studies showed that mutant HEL containing only the D101HELR substitution (HEL3X) bound with ~80-fold lower affinity than HELWT to HyHEL10 (Fig. 1 B), which is in agreement with previous studies (27). Addition of R73HELQ to D101HELR (HEL2X) decreased this affinity ~3-fold, whereas subsequent addition of R21HELQ (HEL3X) reduced it a further ~50-fold. Because HEL3X and HEL2X displayed similar affinities for HyHEL10, only HELWT, HEL2X, and HEL3X were used in subsequent analyses. Based on previous data (18, 26, 27) and our competitive ELISA results, we estimated the affinities of the recombinant HEL proteins for HyHEL10 to be as follows: $2 \times 10^{10} \text{M}^{-1}$ (HELWT), $8 \times 10^{8} \text{M}^{-1}$ (HEL2X), and $1.5 \times 10^{6} \text{M}^{-1}$ (HEL3X). The relative affinity measurements of these mutant proteins are also in agreement with the amount of soluble protein needed to stimulate B cells in vitro. Thus, when activation of purified splenic B cells from SWHEL.rag-1−/− (28) mice was analyzed, 10- and 1,000-fold higher concentrations of HEL2X and HEL3X, respectively, were required to induce comparable levels of intracellular tyrosine phosphorylation to that triggered by HELWT (Fig. 1 C). These recombinant proteins therefore provide the basis for comparing the in vivo responses of SWHEL B cells to high affinity (HELWT), intermediate affinity (HEL3X), and low affinity (HEL2X) antigens.

SWHEL B cells proliferate and form GCs in response to antigens encompassing a 10,000-fold affinity range
To compare T cell–dependent responses to the various HEL proteins, we used a previously described system in which small numbers ($10^6$) of anti-HEL B cells from C57BL/6 (CD45.2+) SWHEL donor mice are adoptively transferred into nonirradiated C57BL/6 congenic (CD45.1+) recipients and challenged intravenously with HEL conjugated to SRBC (2× $10^9$) in the absence of additional adjuvant (6). HEL is linked to SRBC to recruit SRBC-specific T cell help to the SWHEL donor B cells because HEL itself cannot elicit a T cell response.
on the C57BL/6 genetic background (29). In this system, the T cell–dependent response of SWHEL donor B cells can be precisely tracked by multiparameter flow cytometry based on CD45.2 and HEL-binding BCR expression (6). As the recipient mice are nonirradiated, responding B cells can navigate normally through intact peripheral lymphoid tissues where their localization can be readily visualized by immunohistology (6).

We first tested the ability of SWHEL donor B cells to initiate a primary in vivo response when challenged with SRBC conjugates of the various recombinant HEL proteins. Adoptive transfers were performed using CFSE-labeled donor cells and proliferation of the HEL-binding donor cells was measured 64 h later. Extensive proliferation was observed in response to HELWT-SRBC, HEL2X-SRBC, and HEL3X-SRBC. These responses were antigen specific because they did not occur upon challenge with mock-conjugated SRBC (Fig. 2). Although antigen affinity had some effect on the degree of proliferation observed (Fig. 2), SWHEL B cells nevertheless responded efficiently to SRBC conjugates of all three recombinant proteins.

We next examined the ability of the SWHEL donor B cells challenged with the various recombinant HEL proteins to differentiate into GC B cells. By day 5, immunohistological analysis of spleen sections confirmed that there was considerable expansion of HEL-binding B cells in response to each of the recombinant HEL proteins, whereas none was evident in mice challenged with mock-conjugated SRBCs (Fig. 3). Responding HEL-binding B cells were derived from adoptively transferred donor SWHEL B cells because they were not detectable in mice that were challenged with any of the HEL-SRBC conjugates in the absence of cotransferred SWHEL B cells (unpublished data). HEL-binding B cells were found within PNA+ GCs from recipients challenged with each of the three HEL-SRBC conjugates (Fig. 3). By flow cytometry, donor-derived GC B cells were identified on the basis of

Figure 1. Comparison of the abilities of recombinant HEL proteins to bind to and signal through HyHEL10 in vitro. (A) Rasmol space-filling model of HEL showing the mutated residues (colored) within the HyHEL10-binding footprint (light blue). (B) Competitive EUSA showing relative inhibition of the binding of HEL2X-biotin to HyHEL10 by varying concentrations of recombinant HEL proteins. The half-maximal inhibitory concentration for each HEL protein was used to calculate the relative affinities for HyHEL10. (C) Western blot of intracellular tyrosine phosphorylation (pTyr) after 15-min stimulation of SWHEL rag1−/− B cells with varying concentrations of recombinant HEL proteins. Blue, HELWT; orange, HEL1X (D101HEL-R); green, HEL2X (R73HEL-E, D101HEL-R); red, HEL3X (R21HELQ, R73HEL-E, and D101HEL-R).

Figure 2. SWHEL B cells make in vivo proliferative responses to SRBC conjugates of all three recombinant HEL proteins. SWHEL B cells (CD45.1+) were labeled with CFSE and challenged with various HEL-SRBC conjugates by adoptive transfer into CD45.2+ congenic recipients. (A) Pseudocolor FACS plots show the CFSE profile of donor HEL-binding SWHEL B cells in recipient spleens 64 h after challenge with the various HEL-SRBC conjugates. The data shown were gated from total splenocytes after staining with anti–CD45.1-PE. Numbers indicate the frequency of HEL-binding CFSE+ cells among total splenocytes. Data includes a high frequency of contaminant cells (non-HEL binding and CFSE−) present in this analysis as a result of background staining by the anti–CD45.1-PE antibody. Note the lack of proliferating non-HEL–binding cells, indicating that proliferation is antigen specific and that the HEL-binding stain detects all responding SWHEL donor B cells. (B) CFSE profiles are shown for HEL-binding cells present in the gates shown in A. The frequencies of undivided (CFSEhi) cells are shown. Note the increased frequency of dividing cells and their enhanced rate of proliferation (CFSE dilution) as affinity for the HEL antigen is raised.
high surface CD45.2 and HEL binding, relatively low intracellular HEL binding, and lack of syndecan-1 (CD138) expression (Fig. 4). These cells also expressed high levels of GL7 and Fas (CD95; unpublished data). Quantification of the responses to HEL WT-SRBC, HEL 2X-SRBC, and HEL 3X-SRBC revealed that challenge with all three antigens elicited similar numbers of donor-derived (CD45.2+) GC B cells by day 5 (Fig. 5 A). SW HEL donor B cells responding to HEL-SRBC conjugates therefore proliferated and differentiated into GC B cells largely independently of the 10,000-fold variation in their initial affinity for the three recombinant HEL antigens.

Initial BCR affinity regulates the extrafollicular plasma cell response

Variation of antigen affinity, although not affecting GC B cell differentiation, did have a profound impact on the differentiation of SW HEL B cells into extrafollicular proliferative focus plasma cells. Thus, histological analysis of recipient spleens at day 5 revealed that cells exhibiting a plasma cell phenotype (large size and intense cytoplasmic HEL staining) accumulated in the splenic bridging channels and red pulp of mice challenged with HEL WT-SRBC and HEL 2X-SRBC but not in mice challenged with HEL 3X-SRBC (Fig. 3). By flow cytometry, these plasma cells were identifiable on the basis of lower surface CD45.2 and HEL binding compared with GC B cells, very high intracellular HEL binding, and high syndecan-1 expression (Fig. 4). At the peak of the extrafollicular response on day 5, recipients immunized with HEL WT-SRBC and HEL 2X-SRBC contained >100-fold more splenic plasma cells than those challenged with low affinity HEL 3X-SRBC (Fig. 5 B). This was reflected in the relative levels of both total and IgG1 anti-HEL serum antibodies present at this time point (Fig. 5 C and not depicted). These antibodies were derived from the SW HEL donor B cells because they were not detected in mice challenged with any of the HEL-SRBC conjugates in the absence of cotransferred SW HEL B cells (unpublished data). Day 5 plasma cells generated in response to HEL WT-SRBC and HEL 2X-SRBC were confirmed to have originated from extrafollicular foci by the absence of Ig heavy chain variable gene mutations (0/20 and 0/22 clones carried mutations, respectively) in contrast to the SHM already present in corresponding GC B cell populations (10/24 and 4/18 clones mutated, respectively). In this system, therefore, activated SW HEL donor B cells did not undergo differentiation into extrafollicular plasma cells unless their initial
antigen affinity exceeded a threshold value substantially higher than that required for GC B cell differentiation.

**Extrafollicular plasma cell differentiation is also regulated by epitope density**

The regulation of extrafollicular plasma cell differentiation by initial antigen affinity is indicative of a pivotal role for the BCR and its interaction with antigen in determining cell fate during early T-dependent B cell responses. Although antigen affinity alone may be the critical determinant, epitope density can also have a major impact on the strength of the interaction of antigen with the BCR and on subsequent B cell responses (16, 20, 23). To test whether epitope density as well as affinity affects the decision to undergo early plasma cell versus GC B cell differentiation, SW\textsubscript{HEL} B cells were challenged with SRBCs coupled to varying densities of the different recombinant HEL proteins.

Our initial experiments (Figs. 3–5) indicated an apparent affinity threshold for early plasma cell differentiation located between the affinities of HEL\textsuperscript{2X} and HEL\textsuperscript{3X} for the SW\textsubscript{HEL} BCR. To test the influence of antigen density, we asked whether increasing the density of the low affinity HEL\textsuperscript{3X} protein on the SRBC surface might rescue the extrafollicular plasma cell response to this protein and, conversely, whether reducing antigen density might abrogate the extrafollicular response to the intermediate affinity protein HEL\textsuperscript{2X}. In addition to the standard SRBC conjugations using 100 μg/ml HEL\textsuperscript{2X} or HEL\textsuperscript{3X}, separate conjugations were performed using 1,000 μg/ml HEL\textsuperscript{2X} and 10 μg/ml HEL\textsuperscript{2X}. The antigen density on the different SRBC conjugates was compared by flow cytometry using the HyHEL9 mAb. The 100-μg/ml HEL\textsuperscript{2X} and HEL\textsuperscript{3X} conjugates were found to possess almost identical levels of surface antigen (intermediate density), whereas the density was increased threefold for the 1,000-μg/ml HEL\textsuperscript{3X} conjugate (high density) and decreased fourfold for the 10-μg/ml HEL\textsuperscript{2X} conjugate (low density; Fig. 6 A).

SW\textsubscript{HEL} B cells were challenged with the various conjugates in adoptive transfer and their responses analyzed on day 5. When equivalent densities of HEL\textsuperscript{2X} and HEL\textsuperscript{3X} were used (intermediate densities), affinity-based regulation of the early plasma cell response was again apparent, with 20- to 30-fold more extrafollicular plasma cells and antibody being generated in response to HEL\textsuperscript{2X} compared with HEL\textsuperscript{3X} (Fig. 6, B and D–F). When the density of HEL\textsuperscript{3X} on the SRBC was raised threefold (high density), the production of early plasma cells and the secretion of anti-HEL antibody in response to this low affinity antigen were increased almost 10-fold (Fig. 6, B and D–F). Conversely, decreasing the density of HEL\textsuperscript{2X} by fourfold (low density) led to reductions of 5- to 10-fold in the plasma cell and antibody responses to this intermediate affinity antigen (Fig. 6, B and D–F). Importantly, the magnitude of the early GC response did not vary greatly when antigen density was either raised or lowered (Fig. 6, B and C). As a result, the 12-fold difference in epitope density between HEL\textsuperscript{2X}-SRBC (low density) and HEL\textsuperscript{3X}-SRBC (high density) negated the 50-fold affinity difference between these antigens and resulted in almost identical day 5 responses (Fig. 6, B and C). Collectively, these findings indicate that it is the strength of the initial antigen–BCR interaction, influenced by both epitope density and affinity, that determines the extent to which responding B cells enter the extrafollicular plasma cell response.

**Affinity–based partitioning of competing B cells between the early plasma cell and GC compartments**

Although the response of donor SW\textsubscript{HEL} B cells occurs within the context of an endogenous anti-SRBC antibody response, the monoclonal nature of the SW\textsubscript{HEL} BCR does not permit the simultaneous analysis of different B cell specificities responding to the same antigen. The prediction from our finding that the strength of the interaction between antigen and BCR directs cell fate during early T-dependent responses is that B cells expressing alternative BCRs recognizing the same epitope would be differentially represented in the extrafollicular plasma cell compartment depending on the strength of their initial interaction with the antigen. Because epitope density would in this case be fixed, our results predict that the
higher affinity B cells among competing specificities will be preferentially represented in extrafollicular foci compared with early GCs.

To test this prediction, we moved out of the monoclonal SWHEL model to take advantage of the fact that mice carrying the targeted heavy chain variable region gene of HyHEL10 without the light chain transgene (gene-targeted mice expressing only the H chain of HyHEL10) contain B cells with a range of affinities for HEL WT due to pairing of the targeted heavy chain with different endogenous λ light chains (24). In particular, two B cell populations are resolvable by flow cytometry using sub-saturating levels of HEL WT, including a population of relatively high affinity (0.1–0.2% of B cells) and a second population with lower mean affinity for HEL WT (0.2–0.4% of B cells; reference 24; Fig. 7 A). Comparisons of BCR binding by the various recombinant HEL proteins indicated that the affinity for HEL WT of the latter (lower affinity) SWHEL(H) B cell population was still higher than the affinity of the SWHEL BCR for HEL 3X (Fig. S2, available at http://www.jem.org/cgi/content/full/jem.20060087/DC1). For convenience, the second SWHEL(H) B cell population will be referred to as having intermediate affinity for HEL WT.

SWHEL(H) lymph node cells containing 10^4 anti-HEL B cells (high plus intermediate affinity) were adoptively transferred and challenged with HEL WT-SRBC. As a control, SWHEL lymph node cells containing 10^4 anti-HEL B cells (high affinity only) were similarly transferred and challenged. Because the fraction of lymph node B cells that bind HEL in SWHEL mice is typically 5–15%, donor SWHEL lymph node cells were supplemented with a 25-fold excess of WT C57BL/6 lymph node cells so that anti-HEL B cells comprised a similar fraction (0.2–0.6%) of the SWHEL and SWHEL(H) donor B cell populations (Fig. 7 A). A further control group received only WT C57BL/6 lymph node donor cells and so lacked donor B cells with HEL-binding activity (Fig. 7 A). On day 5, CD45.2+ Igκ+ donor-derived B cells (including CD45.2+ Igκ− plasma cells) were collectively analyzed by flow cytometry (Fig. 7 B). The cells were stained with a concentration of HEL WT (75 ng/ml) that resolved the high and intermediate affinity SWHEL(H) responders. Cells were counterstained for surface Ig with anti-κ light chain to identify differences in HEL WT-binding caused by differential antigen affinity rather than BCR expression level (Fig. 7 B). As expected, the anti-HEL WT donor B cells evident in recipients of SWHEL B cells fell almost exclusively within the high-affinity gate, whereas the only donor B cells detected in recipients of WT C57BL/6 lymph node donor cells were resting and did not bind HEL WT (Fig. 7 B).

Analysis of recipients of SWHEL(H) cells indicated that both high and intermediate affinity anti-HEL donor B cell populations had been recruited into the response to HEL WT-SRBC (Fig. 7 B). Importantly, separate analysis of the two responding populations indicated that the proportion of the responding high affinity SWHEL(H) donor B cells that exhibited a plasma cell phenotype was more than double that observed among the intermediate affinity responders (i.e., 45 vs. 21%; Fig. 7 C). Thus, as was predicted from our previous analysis of monoclonal T-dependent responses, the representation of competing B cells in the extrafollicular plasma cell response was greatest for those responders with the highest initial antigen affinity.

**DISCUSSION**

Differential recognition of antigen by BCRs has long been recognized to play a key role in two specific phases of T-dependent B cell responses. The first is when resting B cells are selected to enter the response because this requires the interaction of the BCR with the foreign antigen to exceed a critical threshold. Subsequently, somatically mutated B cells generated within GCs are only propagated if they acquire increased affinity for the antigen presented in immune complexes on follicular dendritic cells. In between these two
mediate affinity for HELWT are evident in SW HEL(H) mice. (B) Lymph node cells therefore injected with the controls receiving just WT C57BL/6 lymph node cells (left) were analyzed separately for the plasma cell (PC) and day 5, splenocytes from recipient mice were stained with 75 ng/ml HEL WTκ as for A and for CD45.2 and Igκ.

Donor B cells were identified with a combination of gates that included CD45.2 hi, Igκ hi resting plus GC B cells, as well as CD45.2 int, Igκ int plasma cells. High and intermediate affinity anti-HELWT B cells were identified as for A. (C) Donor B cells with high and intermediate affinity for HELWT from recipients of SWHEL(H) lymph node cells were analyzed separately for the plasma cell (PC) and...
burst of antibody production to T-dependent antigen is often of relatively high affinity (>10^7 M^−1; references 13–15).

The disparate requirements for high antigen affinity in different T-dependent antibody responses can be reconciled by recognizing that it is the strength of the interaction between antigen and BCR that is crucial for regulating this process, rather than antigen affinity per se. This notion was confirmed in the present study by showing that SWHEL B cells could produce rapid plasma cell and antibody responses to the low affinity HEL3X-SRBC antigen when the density of HEL3X on the SRBC surface was increased (Fig. 6). The presence of low affinity clones in the extracellular focus response to NP-CGG is therefore readily explained by the high epitope density on this haptenated protein antigen, which typically carries 16 NP groups per CGG monomer (31). Our results suggest, therefore, that B cells that recognize low affinity epitopes can still interact sufficiently strongly with antigen to enter the extracellular focus response but only if the epitope is present at relatively high density.

When epitope density is held constant, it is apparent that a 50-fold reduction in antigen affinity (i.e., HEL2X-SRBC to HEL3X-SRBC) can remove the extracellular plasma cell response mounted by SWHEL B cells (Figs. 3–5). Smaller quantitative shifts in the strength of the interaction between the antigen and the BCR by either lowering the density of HEL2X or increasing the density of HEL3X on the SRBC surface had significant but less absolute effects on the early plasma cell response (Fig. 6). Similarly, SWHEL(H) B cells that bound HELWT with intermediate affinity were capable of eliciting a reduced but still clearly evident plasma cell response on day 5 (Fig. 7). Collectively, these results demonstrate that there is not a sharp threshold of interaction between antigen and BCR that determines whether or not early plasma cell differentiation will occur. Rather, within a certain range of interaction strengths, the relative size of the early plasma cell response is directly related to the strength of that initial antigen interaction.

Whether a strong interaction between BCR and antigen is universally required for extracellular focus formation is difficult to assess without studying this question directly using other model antigens. The relatively high affinity of the early antibody response to several T-dependent antigens (13–15) is certainly consistent with BCR-dependent regulation of extracellular plasma cell production also occurring in these cases. Nevertheless, it is possible that adjuvant or other modifying factors alter the quantity or quality of BCR-independently signals delivered to responding B cells by T cells and/or dendritic cells and that these may in turn override the BCR-dependent controls described in the current study. It will be interesting to test this possibility in the future by challenging SWHEL B cells with the different mutant HEL proteins in alternative immunogenic forms.

In contrast to T-dependent antigens, T-independent type 2 (TI-2) antigens such as NP-Ficoll typically generate an extracellular response only. Abortive GCs can be generated but only if antigen dose and precursor frequency are sufficiently high (33). This bias of TI-2 responses toward extracellular focus formation is also evident in the SWHEL system. Thus, when 10^4 HEL-binding SWHEL B cells are challenged with HELWT-Ficoll, short-lived extracellular plasma cells are generated but not GCs (unpublished data). If the observations of T-dependent responses in the current study can also be applied to TI-2 responses, it is possible to attribute the ability of TI-2 antigens to elicit a strong extracellular focus response to the fact that these antigens are typically highly cross-linking (34, 35) and therefore likely to interact strongly with the BCR. In this case, the failure of TI-2 antigens to efficiently generate GCs most likely reflects the importance of T cell help in potentiating GC formation. Alternatively, the strength of BCR engagement may affect T-dependent and TI-2 responses differently, potentially because of modulation in the latter case by co-stimuli delivered through CD21/35 or Toll-like receptor molecules (36).

The finding that quantitative differences in antigen recognition regulate cell fate during early T-dependent B cell responses reveals a sophisticated level of control that has presumably evolved to optimize the deployment of responding B cell clones. Linking rapid plasma cell differentiation to strong initial interaction with antigen means that the substantial resources required to support plasma cell differentiation and subsequent high level antibody production (37) are devoted only to those clones with a good chance of secreting biologically effective antibodies (38). In the case of panvalent epitopes, this effectively means that only relatively high affinity antibodies are produced (Figs. 2–4). However, epitopes present at high density may be effectively neutralized by antibodies of lower affinity (39–41). Under these specific conditions (e.g., high density HEL3X-SRBC), it makes biological sense for low affinity B cells to be permitted into the extracellular plasma cell response (Fig. 6). BCR-mediated regulation of early T-dependent responses also ensures that antigen-specific specificities that make minimal contribution to the initial antibody response are not discarded but specifically directed to GCs. Here they can undergo SHM and affinity maturation and may contribute new effective specificities at a later stage of the response. This is exemplified when SWHEL B cells are challenged with intermediate density HEL3X-SRBC, where the absence of an early (day 5) antibody response (Fig. 5 C) is followed by the subsequent accumulation of high affinity anti-HEL3X antibodies produced by somatically mutated post-GC plasma cells (unpublished data).

The critical role of a strong antigen–BCR interaction in early plasma cell differentiation in vivo is intriguing given that B cells stimulated with T cell–derived signals in vitro undergo efficient proliferation–linked plasma cell differentiation without the need for BCR ligation (32). This dichotomy suggests that B cell differentiation in vivo is influenced by additional signals, which, in the absence of strong antigen recognition, suppress the default plasma cell differentiation pathway. Because responding B cells can proliferate and enter the GC response without undergoing significant plasma cell
differenciation (e.g., HEL<sup>3N</sup>-SRBC response), it is possible that the GC microenvironment may inhibit this process. If this is true, a strong initial interaction between BCR and antigen may allow at least a proportion of the daughter cells of a responding clone to bypass the GC and undergo plasma cell differenciation. The specific mechanism involved is not clear but may be based on BCR-mediated alterations in the expression of chemotactic receptors that facilitate extracellular migration (1). Alternatively, more efficient presentation of antigen-derived peptides facilitated by stronger antigen recognition may result in quantitative or qualitative differences in the delivery of T cell help that influence the subsequent B cell response. A potential clue may lie in the fact that the progressive lowering of initial antigen affinity reduced the rate of proliferation of the anti-HEL B cells during the first 64 h of the response (Fig. 2). It is possible, therefore, that the initial proliferative response may influence the ability of responding cells to undergo rapid plasma cell differenciation. In this case it is possible that signals delivered independently of the antigen–BCR interaction but with the potential to modify B cell proliferation (e.g., Toll-like receptor ligands) may also impact on the size of the extracellular plasma cell response. Studies using the model described here will assist in resolving the specific mechanisms involved and further characterize the signals that shape in vivo B cell responses. Such information holds great promise for the future development of novel therapies for autoimmune diseases as well as the optimization of vaccination strategies.

**MATERIALS AND METHODS**

**Recombinant HEL proteins.** cDNAs encoding the various mutant HEL proteins were produced by site-directed mutagenesis using engineered PCR primers. Sequences encoding the mature WT and mutant HEL proteins were then cloned directly 3′ of the secretory signal sequence in the yeast expression vector pPIC9K (Invitrogen). A COOH-terminal His<sup>6</sup> tag (SGHHHHHHHH) was included in each construct. Transformation of yeast (*Pichia pastoris*) and induction of recombinant HEL expression was performed according to the manufacturer’s instructions. Recombinant HEL proteins were purified from yeast culture supernatants by ion-exchange chromatography using HyTrap SP FF columns followed by N<sup>ε</sup>-affinity chromatography (both from GE Healthcare). Recombinant HEL proteins were >95% pure as determined by SDS-PAGE and staining with Coomassie blue. Yields ranged from 5–15 mg of purified protein from 600 ml of culture supernatant.

**Mice and adoptive transfers.** SW<sub>HEL</sub> (25), SW<sub>HEL</sub>-tag<sup>1–14</sup> (28), and SW<sub>HEL[NH]</sub> (24) mice have been described previously. WT C57BL/6 and CD45.1 congenic C57BL/6 mice were obtained from the Animal Resources Centre (Perth, Australia). All mice were maintained on a C57BL/6 background and housed in specific pathogen–free environment. All experimental procedures were approved by the University of Sydney Animal Ethics Committee. B cell isolation, CFSE labeling, and conjugation of HEL to SRBC were performed as described previously (26). SRBC conjugates were performed using recombinant WT or mutant HEL at 100 μg/ml unless otherwise indicated (Fig. 6). For adoptive transfers, spleen or lymph node cells from SW<sub>HEL</sub> or SW<sub>HEL[NH]</sub> donor mice containing 10<sup>6</sup> HEL-binding B cells were injected intravenously into male C57BL/6 recipients together with 2 × 10<sup>6</sup> SRBC conjugated to a specific recombinant HEL protein. Mock-conjugated SRBC in which HEL was omitted from the conjugation reaction served as a control antigen. No additional adjuvant was used in the immunizations. Mice receiving only HEL-conjugated SRBCs intravenously did not produce detectable anti-HEL serum antibodies, presumably because of the low frequency of anti-HEL B cells present in the absence of transferred SW<sub>HEL</sub> B cells.

**ELISAs.** Anti-HEL antibody levels in sera from immunized mice were analyzed by ELISA as described previously (25). Competitive ELISA was performed to measure the relative affinities of the mutant HEL for HyHEL10. For this, plates were first coated with purified HyHEL10, after which 50 ng/ml of biotinylated HEL<sup>WT</sup> was added in conjunction with varying concentrations of unlabelled recombinant HEL<sup>WT</sup>, HEL<sup>3N</sup>, HEL<sup>2S</sup>, and HEL<sup>NH</sup>. Non-linear regression based on a one-site competition model was performed using GraphPad Prism software to find the curve-fit and calculate the half-maximal inhibitory concentration.

**Western blotting.** SW<sub>HEL-tag</sub><sup>1–14</sup> B cells were isolated and stimulated with varying concentrations of recombinant HEL proteins for 15 min at 37°C, and whole cell lysates were prepared in buffer containing protease and phosphatase inhibitors as described previously (42). Proteins were separated by SDS-PAGE and membranes probed with mouse antiphosphotyrosine (Upstate Biotechnology) followed by goat anti-mouse IgG–horseradish peroxidase (Santa Cruz Biotechnology, Inc.) and developed with enhanced chemiluminescence (Perbio). Blots were stripped and re-probed with anti-actin antibody (Santa Cruz Biotechnology, Inc.) to control for protein loading.

**Immunohistology.** Splenic sections were stained for GCs and HEL–binding B cells as previously described (6).

**FACS analysis.** Splenocytes were prepared, stained for surface molecules, and analyzed on a FACSCalibur (BD Biosciences) as previously described (6). Intracellular staining to detect cytoplasmic HEL–binding Ig was performed after fixation with 10% formalin and permeabilization with 0.2% polyethylen glycol sorbitan monolaurate. GC B cells (low intracellular HEL binding and syndecan-1 expression) and plasma cells (high intracellular HEL binding and syndecan-1 expression) were enumerated using the gates shown in Fig. 4 B. B cells in mice challenged with mock-SRBC fell in the GC B cell gate but were not counted as they had not proliferated (Fig. 2), did not express GL7 (not depicted), and were shown histologically to be absent from GC (Fig. 3 D).

**SHM analysis.** Single responding SW<sub>HEL</sub> B cells were sorted from the spleens of recipient mice 5 d after transfer using a FACSVerse (BD Biosciences). GC and plasma cells were identified using the gates shown in Fig. S1 (available at http://www.jem.org/cgi/content/full/jem.20060308/DC1) and single cells sorted into 96-well plates containing proteinase K (Sigma–Aldrich). The variable region exon of the SW<sub>HEL</sub> Ig (HyHEL10) heavy chain gene was then PCR amplified using Taq polymerase (Sigma–Aldrich) for 35 cycles with the primers GTGTAGCCCTAAAAAGATGTGGTG and GATACTCTGTCCTAAAAGCTCTGAG. The primary PCR product was further amplified for 35 cycles with the nested primers TTGTAGACCTAAAAGATGTGGTGTTAAGTC and ACACTCTCTACGGCGGCCT. The final PCR product was sequenced with the dideoxy–chain termination method using primer TTGTAGCCTAAAAGATGTGGTGTTAAGTC at the Australian Genomic Research Foundation (Brisbane, Australia). Sequences encoding the mature VDJ region were analyzed for the presence of SHM events.

**Online supplemental material.** Fig. S1 shows the FACS gating strategy for sorting single cells with the GC and plasma cell phenotypes. Fig. S2 shows the binding of the various mutant HEL proteins to both SW<sub>HEL</sub> and SW<sub>HEL[NH]</sub> B cells. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20060308/DC1.

We thank Jenny Kingham and the Centenary Institute Animal Facility staff for animal husbandry, Chris Brownlee and Michelle Amesbury for mouse screening, Adrian Smith and Vivienne Moore for FACS sorting, and Stephen Adelstein and Stuart Tangey for critical review of the manuscript.
REFERENCES

1. MacLennan, I.C., K.M. Twedtner, A.F. Cunningham, K. Serre, D.M. Sun, E. Zangna, M.C. Cook, and C.G. Vinuesa. 2003. Extrafollicular antibody responses. Immunol. Rev. 194:18–18.

2. Liu, Y.J., J. Zhang, P.J. Lane, E.Y. Chan, and I.C. MacLennan. 1991. Sites of specific B cell activation in primary and secondary responses to T cell-dependent and T cell-independent antigens. Eur. J. Immunol. 21:2951–2962.

3. Jacob, J., R. Kasir, and G. Kelsoe. 1991. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl I. The architecture and dynamics of responding cell populations. J. Exp. Med. 173:1165–1175.

4. Garside, P., E. Ingulli, R.R. Merica, J.G. Johnson, R.J. Noelle, and S.L. Nutt. 1993. Visualization of specific B and T lymphocyte interactions in the lymph node. Science. 281:96–99.

5. Jacob, J., and G. Kelsoe. 1992. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl II. A common clonal origin for periaorterolar lymphoid sheath-associated foci and germinal centers. J. Exp. Med. 176:679–687.

6. Phan, T.G., S. Gardam, A. Baxten, and R. Brink. 2005. Altered migration, recruitment, and somatic hypermutation in the early response of germinal center B cells to T cell-dependent antigen. J. Immunol. 174: 4567–4578.

7. McHeyzer-Williams, M.G., M.J. McLean, P.A. Lalor, and G.J. Nossal. 1993. Antigen-driven B cell differentiation in vivo. J. Exp. Med. 178:295–307.

8. Jacob, J., G. Kelsoe, K. Rajewsky, and U. Weiss. 1991. Intracral generation of antibody mutants in germinal centers. Nature. 354: 389–392.

9. Berek, C., A. Berger, and M. Apel. 1991. Maturation of the immune response in germinal centers. Cell. 67:1121–1129.

10. Takahashi, Y., P.R. Dutta, D.M. Cerasoli, and G. Kelsoe. 1998. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl V. Affinity maturation develops in two stages of clonal selection. J. Exp. Med. 187:885–895.

11. Dal Porto, J.M., A.M. Haberman, M.J. Slomchik, and G. Kelsoe. 1998. Antigen drives very low affinity B cells to become plasmacytes and enter germinal centers. J. Immunol. 161:5373–5381.

12. Bink, E.J., A. Light, A. Kallies, S.L. Nuss, P.D. Hodgkin, and D.M. Tarlinton. 2005. Early appearance of germinal center–derived memory B cells and plasma cells in blood after primary immunization. J. Exp. Med. 201:545–554.

13. Newman, M.A., C.R. Mainhart, C.P. Mallett, T.B. Lavoie, and M.A. Newman. 1991. Antigen-driven B cell differentiation in vivo. J. Exp. Med. 173:1165–1175.

14. Roost, H.P., M.F. Bachmann, A. Haag, U. Kalinke, V. Pliska, H. Hengartner, and R.M. Zinkernagel. 1995. Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity. Proc. Natl. Acad. Sci. USA. 92:1257–1261.

15. Foote, J., and H.N. Eisen. 1995. Kinetic and affinity limits on antibodies produced during immune responses. Proc. Natl. Acad. Sci. USA. 92:1254–1256.

16. Royter, C.D., M.K. Kriz, T.J. Sullivan, and E.S. Vitetta. 1987. Antigen-induced changes in phospholipid metabolism in antigen-binding B lymphocytes. J. Immunol. 138:1705–1711.

17. Mongini, P.K., C.A. Blessinger, and J.P. Dalton. 1991. Affinity requirements for induction of sequential phases of human B cell activation by membrane IgM-cross-linking ligands. J. Immunol. 146: 1791–1800.

18. Batista, F.D., and M.S. Neuberger. 1998. Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. Immunity. 8:751–759.

19. Kouskoff, V., S. Famiglietti, G. Lacaud, P. Lang, J.E. Rider, B.K. Kay, J.C. Cambier, and D. Nemazee. 1998. Antigens varying in affinity for the B cell receptor induce differential B lymphocyte responses. J. Exp. Med. 188:1453–1464.

20. Dintzis, H.M., R.Z. Dintzis, and B. Vogelstein. 1976. Molecular determinants of immunogenicity: the immunon model of immune response. Proc. Natl. Acad. Sci. USA. 73:3671–3675.

21. Shih, T.A., M. Roederer, and M.C. Nussenzweig. 2002. Role of antigen receptor affinity in T cell-independent antibody responses in vivo. Nat. Immunol. 3:399–406.

22. Nemazee, D.A., and K. Burki. 1989. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature. 337:562–566.

23. Hartley, S.B., J. Croabie, R. Brink, A.B. Kantor, A. Baxten, and C.C. Goodnow. 1991. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature. 354: 1791–1800.

24. Thienn, M.T., T.G. Phan, S. Gardam, M. Amesbury, A. Baxten, F. Mackay, and R. Brink. 2004. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 20:785–798.

25. Phan, T.G., M. Amesbury, S. Gardam, J. Croabie, J. Hasbold, P.D. Hodgkin, A. Baxten, and R. Brink. 2003. B cell receptor-independent stimuli trigger immunglobulin (Ig) class switch recombination and production of IgG autoantibodies by anergic self-reactive B cells. J. Exp. Med. 197:845–860.

26. Padlan, E.A., E.W. Silverton, S. Shreff, G.H. Cohen, S.J. Smith-Gill, and D.R. Davies. 1989. Structure of an antibody-antigen complex: crystal structure of the NyHEL-10 Fab-lysozyme complex. Proc. Natl. Acad. Sci. USA. 86:5938–5942.

27. Taylor, M.G., A. Rajapal, and J.F. Kirsch. 1998. Kinetic epitope mapping of the chicken lysozyme.HyHEL-10 Fab complex: delineation of docking trajectories. Protein Sci. 7:1857–1867.

28. Cook, A.J., L. Oganestan, P. Harumal, A. Baxten, R. Brink, and C.J. Jolly. 2003. Reduced switching in SCID B cells is associated with altered somatic mutation of recombined S regions. J. Immunol. 171: 6556–6564.

29. Gammon, G., N. Shastrl, J. Cogwell, S. Wilbru, S. Dagenh-Nasserl, U. Kryzch, A. Miller, and E. Sercez. 1987. The choice of T-cell epitopes utilized on a protein antigen depends on multiple factors distant from, as well as at the determinant site. Immunol. Rev. 98:53–73.

30. Shih, T.A., E. Meffre, M. Roederer, and M.C. Nussenzweig. 2002. Role of BCR affinity in T cell dependent antibody responses in vivo. Nat. Immunol. 3:570–575.

31. Dal Porto, J.M., A.M. Haberman, G. Kelsoe, and M.J. Slomchik. 2002. Very low affinity B cells form germinal centers, become memory B cells, and participate in secondary immune responses when higher affinity competition is reduced. J. Exp. Med. 195:1215–1221.

32. Hasbold, J., L.M. Corcoran, D.M. Tarlinton, S.G. Tangye, and P.D. Hodgkin. 2004. Evidence from the generation of immunoglobulin G-secreting cells that stochastic mechanisms regulate lymphocyte differentiation. Nat. Immunol. 5:356–365.

33. de Vinuea, C.G., M.C. Cook, J. Ball, M. Drew, Y. Sunners, M. Cascallo, M. Wahl, G.G. Klaus, and I.C. MacLennan. 2000. Germinal centers without T cells. J. Exp. Med. 191:485–494.

34. Dintzis, R.Z., M. Okajima, M.H. Middleton, G. Greene, and H.M. Dintzis. 1989. The immunogenicity of soluble haptenated polymers is determined by molecular mass and hapten valency. J. Immunol. 143: 1239–1244.

35. Mongini, P.K., C.A. Blessinger, P.F. Hight, and J.K. Imman. 1992. Membrane IgM-mediated signaling of human B cells. Effect of increased ligand binding site valency on the affinity and concentration requirements for inducing diverse stages of activation. J. Immunol. 148:3892–3901.

36. Vos, Q., A. Lees, Z.Q. Wu, C.M. Snapper, and J.J. Mond. 2000. B-cell activation by T-cell-independent type 2 antigens as an integral part of
the humoral immune response to pathogenic microorganisms. *Immunol. Rev.* 176:154–170.

37. Ma, Y., and L.M. Hendershot. 2003. The stressful road to antibody secretion. *Nat. Immunol.* 4:310–311.

38. Bachmann, M.F., and R.M. Zinkernagel. 1997. Neutralizing antiviral B cell responses. *Annu. Rev. Immunol.* 15:235–270.

39. Briles, D.E., C. Forman, S. Hudak, and J.L. Claffin. 1982. Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against *Streptococcus pneumoniae*. *J. Exp. Med.* 156:1177–1185.

40. Oda, M., and T. Azuma. 2000. Reevaluation of stoichiometry and affinity/avidity in interactions between anti-hapten antibodies and mono- or multi-valent antigens. *Mol. Immunol.* 37:1111–1122.

41. Tobita, T., M. Oda, and T. Azuma. 2004. Segmental flexibility and avidity of IgM in the interaction of polyvalent antigens. *Mol. Immunol.* 40:803–811.

42. Tangye, S.G., B.C. van de Weerd, D.T. Avery, and P.D. Hodgkin. 2002. CD84 is up-regulated on a major population of human memory B cells and recruits the SH2 domain containing proteins SAP and EAT-2. *Eur. J. Immunol.* 32:1640–1649.